signature=29a4ea314a711e460a5ee62b12d09e03,The Hydrogen Sulfide-Vitamin B12-Folic Acid Axis: An Intr...

摘要：

4. Collins, A.; Foley, R.; Chavers, B.; Gilbertson, D.; Herzog, C.; Johansen, K.; Kasiske, B.L.; Kutner, N.; Liu, J.; St Peter, W.; et al. US Renal Data System 2013 Annual Data Report. Am. J. Kidney Dis. 2014, 63, E1-E460. [CrossRef] [PubMed]5. De Koning, L.; Hu, F.B. Homocysteine lowering in end-stage renal disease: Is there any cardiovascular benefit? Circulation 2010, 121, 1379-1381. [CrossRef] [PubMed]6. Heinz, J.; Kropf, S.; Luley, C.; Dierkes, J. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: A meta-analysis. Am. J. Kidney Dis. 2009, 54, 478-489. [CrossRef] [PubMed]7. Perna, A.F.; Ingrosso, D.; Violetti, E.; Luciano, M.G.; Sepe, I.; Lanza, D.; Capasso, R.; Ascione, E.; Raiola, I.; Lombardi, C.; et al. Hyperhomocysteinemia in uremia--A red flag in a disrupted circuit. Semin. Dial. 2009, 22, 351-356. [CrossRef] [PubMed]8. Cianciolo, G.; La Manna, G.; Coli, L.; Donati, G.; D'Addio, F.; Persici, E.; Comai, G.; Wratten, M.; Dormi, A.; Mantovani, V.; et al. 5-methyltetrahydrofolate administration is associated with prolonged survival and reduced inflammation in ESRD patients. Am. J. Nephrol. 2008, 28, 941-948. [CrossRef] [PubMed]9. Marti, F.; Vollenweider, P.; Marques-Vidal, P.M.; Mooser, V.; Waeber, G.; Paccaud, F.; Bochud, M. Hyperhomocysteinemia is independently associated with albuminuria in the population-based CoLaus study. BMC Public Health 2011, 11, 733. [CrossRef] [PubMed]10. Welch, G.N.; Loscalzo, J. Homocysteine and atherothrombosis. N. Engl. J. Med. 1998, 338, 1042-1050. [PubMed]11. House, A.A.; Eliasziw, M.; Cattran, D.C.; Churchill, D.N.; Oliver, M.J.; Fine, A.; Dresser, G.K.; Spence, J.D. Effect of B-vitamin therapy on progression of diabetic nephropathy: A randomized controlled trial. Jama 2010, 303, 1603-1609. [CrossRef] [PubMed]12. Xu, X.; Qin, X.; Li, Y.; Sun, D.; Wang, J.; Liang, M.; Wang, B.; Huo, Y.; Hou, F.F. Efficacy of Folic Acid Therapy on the Progression of Chronic Kidney Disease: The Renal Substudy of the China Stroke Primary Prevention Trial. JAMA Intern. Med. 2016, 176, 1443-1450. [CrossRef] [PubMed]13. Wang, R. Two's company, three's a crowd: Can H2S be the third endogenous gaseous transmitter? FASEB J. 2002, 16, 1792-1798. [CrossRef] [PubMed]14. Perna, A.F.; Sepe, I.; Lanza, D.; Capasso, R.; Di Marino, V.; De Santo, N.G.; Ingrosso, D. The gasotransmitter hydrogen sulfide in hemodialysis patients. J. Nephrol. 2010, 23, S92-S96. [PubMed]15. Li, H.; Feng, S.J.; Zhang, G.Z.; Wang, S.X. Correlation of lower concentrations of hydrogen sulfide with atherosclerosis in chronic hemodialysis patients with diabetic nephropathy. Blood Purif. 2014, 38, 188-194. [CrossRef] [PubMed]16. Feng, S.J.; Li, H.; Wang, S.X. Lower Hydrogen Sulfide Is Associated with Cardiovascular Mortality, Which Involves cPKCβII/Akt Pathway in Chronic Hemodialysis Patients. Blood Purif. 2015, 40, 260-269. [CrossRef] [PubMed]17. Harja, E.; Chang, J.S.; Lu, Y.; Leitges, M.; Zou, Y.S.; Schmidt, A.M.; Yan, S.F. Mice deficient in PKCbeta and Apolipoprotein E display decreased atherosclerosis. FASEB J. 2009, 23, 1081-1091. [CrossRef] [PubMed]18. Ferreira, J.C.; Koyanagi, T.; Palaniyandi, S.S.; Fajardo, G.; Churchill, E.N.; Budas, G.; Disatnik, M.H.; Bernstein, D.; Brum, P.C.; Mochly-Rosen, D. Pharmacological inhibition of βIIPKC is cardioprotective in late-stage hypertrophy. J. Mol. Cell. Cardiol. 2011, 51, 980-987. [CrossRef] [PubMed]

展开